Supreme Court Speeds Copycat Biologic Drugs to Market

Supreme Court Speeds Copycat Biologic Drugs to Market


The U.S. Supreme Court on Monday cut the time it will take for copycat versions of biologic drugs to get to the market in a pivotal ruling about an expensive class of medicines that can yield billions of dollars in sales for drug companies. The justices, in a 9-0 ruling, overturned a lower court's decision that had prevented Swiss pharmaceutical company Novartis AG from selling its copycat version of California-based Amgen Inc's Neupogen until six months after the U.S. Food and Drug Administration approved it.



from Biotech News